1

Therapies for treatment-resistant depression : neuropharmacology and neurostimulation

Favoris Imprimer
Livre électronique

Murrough, James W. (Éditeur intellectuel) / Charney, Dennis S. (Éditeur intellectuel)

Academic Press

2025

1 ressource en ligne (xxvi, 376 pages) : illustrations (chiefly color)

Format PDF

9780443160059

Anglais

Treatment-resistant depression: epidemiology and clinical presentation -- Molecular neuropharmacology of treatment-resistant depression -- Neurobiology and neuroimaging of treatment resistant depression -- Pharmacotherapy of treatment-resistant depression: overview and look ahead -- Lithium, dopamine modulators, and other augmentation strategies for treatment-resistant depression -- Ketamine and esketamine for treatment-resistant depression -- Impact of inflammation on treatment resistance in depression: mechanisms and translational opportunities -- Novel pharmacotherapies for treatment-resistant depression: a focus on glutamate and gamma-aminobutyric acid modulators -- Electroconvulsive therapy for treatment-resistant depression -- Transcranial magnetic stimulation for treatment-resistant depression -- Vagal nerve stimulation for treatment-resistant depression -- Deep brain stimulation for treatment-resistant depression -- Psilocybin and other psychedelic agents in development for treatment-resistant depression -- Neuroimaging biomarkers in treatment selection for treatment-resistant depression -- The role of genetics in treatment-resistant depression.

Provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders. The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.

Dépression - Traitement / Neuropharmacologie / Électrothérapie

Accéder au texte intégral